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costs. In a health care system like Ontario’s, which treats 2800 new breast cancer 
patients per year, this may represent a signiﬁ cant reduction in operation cost. These
savings should be considered in context of how much resource investment is required
to reduce waiting.
PCN68
COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST
LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD
AND NECK (SCCHN) IN CANADA
Sambrook JC1, Levy AR1, Johnston KM2, Ricard NJ3, Bourgault C3, Donato BM4, Hotte SJ5, 
Chasen MR6, Briggs A7
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, 
BC, Canada, 3Bristol-Myers Squibb Canada, St-Laurent, QC, Canada, 4Bristol-Myers Squibb, 
Wallingford, CT, USA, 5McMaster University, Hamilton, ON, Canada, 6McGill University, 
Montreal, QC, Canada, 7University of Glasgow, Glasgow, UK
OBJECTIVES: Squamous cell carcinoma of the head and neck (SCCHN) can be a 
devasting disease. Cetuximab has recently been shown to improve locoregional control
(LRC) and reduce mortality in locally and regionally advanced disease. The objective
of the study is to estimate the incremental cost-utility of cetuximab plus radiotherapy 
(CxRT) versus cisplatin plus radiotherapy (CsRT) among platinum eligible patients
and versus RT alone in platinum ineligible patients in Canada. METHODS: A lifetime 
transition model was developed with four health states: 1) acute treatment phase; 2)
LRC; 3) disease progression and 4) death. Adverse events were accounted for in the
ﬁ rst two states. Efﬁ cacy of treatment (LRC and overall survival) was obtained from 
the literature. Based on network meta-analyses, CsRT and CxRT were assumed to
have equal efﬁ cacy. Resource use was obtained from published literature and clinical 
expert opinion. The perspective adopted was that of a provincial ministry of health
or cancer agency. Utilities were obtained from a previous study of UK oncology nurses.
Costs (CDN$2008) and outcomes were discounted at 5% annually. Incremental cost-
effectiveness ratios (ICERs) were reported with one-way and probabilistic sensitivity
analyses performed to assess robustness of results. A priori sub-group analyses were 
carried out by baseline Karnofsky Performance Scores (KPS). RESULTS: Among 
all patients (KPS 60–100), the ICERs comparing CxRT to RT were $19,740/QALY 
(95% CI: $11,122 to $695,295) among platinum ineligible patients and for CxRT vs. 
CsRT, $99,147/QALY (95% CI: $75,998 to $148,951) among platinum eligible 
patients. ICERs decreased with increasing KPS scores. At a willingness-to-pay of 
$50,000 among platinum-ineligible patients and $100,000 among platinum-eligible
patients, the likelihood that CxRT is cost-effective is 90% and 45% respectively. Sen-
sitivity analyses indicated that time horizon and assumptions about CsRT effectiveness
had the largest impact on results. CONCLUSIONS: Cetuximab is an economically
attractive option for SCCHN patients.
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OBJECTIVES: To determine incremental costs and life expectancy of adding bevaci-
zumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin (5-FU/LV) 
regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic colorectal 
cancer (MCRC) in the UK. METHODS: We performed a decision analysis with a
THREE-health-state area under the curve model to explore the effects of adding bev 
treatment to an existing FOLFIRI-based regimen. The model structure was based on
a published model by National Institute of Technology Excellence (NICE), UK. Pro-
gression-free (PFS) and overall survival (OS) data were derived from clinical trials 
comparing bevirinotecan and 5-FU/LV (IFL) with IFL alone. The impact on OS for 
bevFOLFIRI was included through an indirect comparison of hazard ratios (HRs)
between bevmIFL versus bevFOLFIRI (HR for death: 1.79; 95% CI: 1.12–2.88).
Treatment effect for bevFOLFIRI was maintained during the 40-month clinical
follow-up. The FOLFIRI PFS was created by applying the HR from IFL versus
FOLFIRI (HR for progression or death: 1.51, 95% CI: 1.16–1.97) to the IFL PFS. 
Outcomes included life years, QALYs, direct costs and incremental cost-effectiveness 
ratios (ICERs). A life-time horizon (8 years) was used. Cost and outcomes were dis-
counted by 3.5% per annum. Both deterministic and probabilistic sensitivity analyses 
were performed. RESULTS: The estimated discounted life expectancy for bevFOLFIRI-
treated patients was 2.62 years (undiscounted: 2.77 years) versus 1.58 years (undis-
counted: 1.63 years) in the FOLFIRI arm. The discounted costs in the 2 arms were
a49,798 and a23,698, respectively. The discounted ICER was a25,045 per life-year
gained and a40,532 per QALY gained. Sensitivity analysis on key variables showed
that assumptions of size (HR) and duration of treatment effect were the most inﬂ u-
ential factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC increases survival for these patients and is a cost
effective treatment option.
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OBJECTIVES: To model expected mean incremental costs and life expectancy of 
adding bevacizumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin
(5-FU/LV) regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic 
colorectal cancer (MCRC) in Sweden. METHODS: A 3-health-state model explored 
the effects of adding bev treatment to an existing FOLFIRI-based regimen. The model
structure was based on one published by National Institute for Health and Clinical
Excellence (NICE) UK, which applies to guidelines established by the Swedish Phar-
maceutical and Dental Beneﬁ ts Board. Progression-free (PFS) and overall survival (OS)
data are derived from clinical trials comparing bevirinotecan and 5-FU/LV (IFL) with 
IFL alone. The impact on OS for bevFOLFIRI was included through an indirect 
comparison of hazard ratios (HRs) between bevmIFL versus bevFOLFIRI (HR for 
death: 1.79; 95%CI: 1.12–2.88). Treatment effect for bevFOLFIRI was maintained
during the 40-month clinical follow-up. The FOLFIRI PFS was created by applying 
the HR from IFL versus FOLFIRI (HR for progression or death: 1.51, 95%CI: 1.16–
1.97) to the IFL PFS. Outcomes included life years, QALYs, direct costs and incre-
mental cost-effectiveness ratios (ICERs). A life-time horizon (eight years) was used.
Cost and outcomes were discounted by 3% per annum. RESULTS: The estimated 
mean life expectancy for bevFOLFIRI-treated patients was 2.64 years (discounted; 
2.77 years undiscounted) versus 1.58 years (discounted; 1.63 years undiscounted) in 
the FOLFIRI arm. The discounted costs in the 2 arms were 525,404 SEK and 245,775
SEK, respectively. The discounted ICER was 264,689 SEK/life-year gained and 
428,519 SEK/QALY gained. Sensitivity analysis on key variables showed that assump-
tions of size (HR) of treatment effect and duration of treatment effect were the most 
critical factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC is predicted to increase survival for these patients 
and also be a cost-effective treatment option in Sweden.
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OBJECTIVES: In EGF100151, lapatinib plus capecitabine (LC) improved time to 
progression (TTP) vs C-only (Median 27.1 vs 18.6 wks, HR  0.57, p  0.001) in 
women with ErbB2 MBC who had received prior CT with TZ, anthracyclines, and 
taxanes. In GBG26, TZ plus capecitabine (TZC) improved TTP vs C-only in ErbB2
MBC patients with prior TZ and a1 prior courses of palliative CT (n  74 vs 77, 
median 36.9 vs 24.3 wks, HR  0.69, p  0.034). Because 50% of EGF100151 
patients had received q4 prior lines of CT, results of EGF100151 and GBG26 are not 
directly comparable. The objective of this analysis was to evaluate (1) the CE (cost 
per quality-adjusted life year [QALY] gained) of TZC vs C-only in GBG26 and 
(2) the CE of LC vs C-only in a subgroup of comparable EGF100151 patients 
(3 CT, n  31 vs 37, TTP: Median 49.4 vs 19.7 wks, HR  0.37, p  0.0059, OS: 
Median 87.3 vs 55.1 wks, HR  0.51, p  0.0140). METHODS: Trial-based survival 
analyses were conducted of GBG26 patients and of EGF100151 patients with 3 CT, 
with progression-free survival (PFS) and OS for each treatment arm estimated by
ﬁ tting Weibull survival functions to failure-time data. A UK National Health Service 
perspective was employed. Costs and utilities were estimated using data from 
EGF100151 and the literature. RESULTS: The increase in QALYs for LC vs C-only 
among EGF100151 patients with 3 CT is 0.462; for TZC vs C-only in GBG26,
0.167. The increase in costs for LC vs C-only among EGF100151 patients with 3 
CT is a24,094; for TZC vs C-only in GBG26, a23,198. CE with LC vs C-only 
among EGF100151 patients with 3 CT is a52,152/QALY; for TZC vs C-only in 
GBG26, a138,910/QALY. CONCLUSIONS: In TZ-refractory ErbB2 MBC patients
with limited CT exposure, CE of LC vs C-only may be more favorable than CE of 
TZC vs C-only.
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OBJECTIVES: Calculate life expectancy and quality of life of geﬁ tinib versus docetaxel 
in the treatment of non-small-cell lung cancer in a Mexican public institution (ISSSTE).
METHODS: A Discrete Event Simulation model was designed to emulate probabilities 
of having one or more adverse events at the same time when in treatment for
